Summit Therapeutics (SMMT) Receives a Hold from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Summit Therapeutics (SMMT) today. The company’s shares opened today at $1.88, close to its 52-week low of $1.10.

According to, Singh is a 3-star analyst with an average return of 3.1% and a 47.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Summit Therapeutics is a Moderate Buy with an average price target of $2.

See today’s analyst top recommended stocks >>

Based on Summit Therapeutics’ latest earnings release for the quarter ending October 31, the company reported a quarterly GAAP net loss of $10.55 million. In comparison, last year the company had a GAAP net loss of $15.53 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts